Search
Tango Therapeutics Inc
TNGXAdd to Watchlist
27.180USD
-0.390-1.41%
Close 07-31 16:00（ET）Quotes delayed by 15 min
3.69BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Tango Therapeutics Inc is 8.67, ranking 74 out of 385 in the Biotechnology & Medical Research industry. The average price target is 13.50, with a high of 15.00 and a low of 11.00.
Analyst Rating
Based on
13
analysts
Buy
Current Rating
44.182
Target Price
+70.92%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Tango Therapeutics Inc
TNGX
13
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
26
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Tango Therapeutics Inc's price target?
Analysts forecast that Tango Therapeutics Inc's price target is USD 13.50, with the highest forecast at USD 15.00 and the lowest forecast at USD 11.00.
How have Tango Therapeutics IncTNGX's recent earnings per share performed?
The market expectation was USD -0.32, while Tango Therapeutics IncTNGX's earnings per share (EPS) for the previous quarter was USD -0.29. EPS for the next quarter is expected at USD -0.32.
What is the analyst rating for Tango Therapeutics Inc?
Based on the ratings of Tango Therapeutics Inc's stock from 13 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.